CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol
CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol
Study Summaries
NRG-GY012: Olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
NRG-GY012
DESKTOP Trial - Secondary Debulking Surgery
Secondary debulking surgery in recurrent ovarian cancer
PORTEC 2: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk
Vaginal Brachytherapy vs. Pelvic External Beam Radiotherapy in Endometrial Cancer (PORTEC-2)
RUBY - Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
NRG GY018: Pembrolizumab in Advanced Endometrial Cancer
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
MITO-7: Weekly chemotherapy in ovarian cancer
Weekly chemotherapy vs. q3 weekly chemotherapy in advanced ovarian cancer
BEATcc: Atezolizumab added to Cis/Taxol/Bev in recurrent/metastatic cervical cancer
Atezolizumab plus bevacizumab and chemotherapy for
metastatic, persistent, or recurrent cervical cancer (BEATcc)
GOG 281: Trametinib in recurrent low-grade serous ovarian cancer
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer.
MIRASOL: Mirvetuximab in Platinum Resistant Cancer
Mirvetuximab Soravtansine (MIRV) in platinum resistant ovarian cancer